Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT

Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT

Background Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome affects ~100 United Kingdom children each year. Around half need dialysis, a quarter develop serious complications with long-term consequences and ~3% die. No effective intervention is known; however, some studies report e...

Full description

Bibliographic Details
Main Authors: Natalie Ives, Rebecca Woolley, Moin A Saleem, Catherine A Moakes, Aoife Waters, Rodney D Gilbert, Hugh Jarrett, Elizabeth Brettell, Steve Nash, Louise K Farmer, Khadija Ourradi, Sally A Johnson
Format: Article
Language:English
Published: NIHR Journals Library 2024-07-01
Series:Efficacy and Mechanism Evaluation
Subjects:
humans
child
randomised controlled trial
acute kidney injury
shiga-toxigenic escherichia coli
shiga toxin
haemolytic uraemic syndrome
complement activation
eculizumab
severity of illness index
podocytes
vascular endothelial growth factor
united kingdom (mesh)
Online Access:https://doi.org/10.3310/RFTY4766

Internet

https://doi.org/10.3310/RFTY4766

Similar Items